AmerisourceBergen Corp. Company Profile (NYSE:ABC)

AmerisourceBergen Corp. trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABC."

AmerisourceBergen Corp. declared a quarterly dividend on Tuesday, May 9th. Stockholders of record on Monday, May 22nd will be given a dividend of $0.365 per share on Monday, June 5th. This represents a $1.46 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date of this dividend is Thursday, May 18th. View AmerisourceBergen Corp.'s Dividend History.

AmerisourceBergen Corp. (NYSE:ABC) announced its quarterly earnings results on Thursday, May, 4th. The company reported $1.77 EPS for the quarter, beating the Zacks' consensus estimate of $1.68 by $0.09. The business had revenue of $37.15 billion for the quarter, compared to the consensus estimate of $38.07 billion. AmerisourceBergen Corp. had a net margin of 0.91% and a return on equity of 62.44%. AmerisourceBergen Corp.'s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.68 EPS. View AmerisourceBergen Corp.'s Earnings History.

AmerisourceBergen Corp. is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for AmerisourceBergen Corp..

AmerisourceBergen Corp. issued an update on its FY17 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $5.77-5.92 for the period, compared to the Thomson Reuters consensus estimate of $5.82. The company issued revenue guidance of ~$154.9-156.4 billion (+5.5-6.5% y/y), compared to the consensus revenue estimate of $156.38 billion.

15 equities research analysts have issued 12 month price objectives for AmerisourceBergen Corp.'s stock. Their predictions range from $83.00 to $105.00. On average, they anticipate AmerisourceBergen Corp.'s stock price to reach $93.63 in the next twelve months. View Analyst Ratings for AmerisourceBergen Corp..

Here are some recent quotes from research analysts about AmerisourceBergen Corp. stock:

• 1. According to Zacks Investment Research, "AmerisourceBergen posted mixed first quarter 2017 results with earnings beating the Zacks Consensus Estimate and sales missing the same. However the company’s outcome on a year-over-year basis made a mark. The mixed performance, however, did not have much affected its share price banking on a stable 2017 issued guidance. Notably, in the last three months, AmerisourceBergen has outpaced the Zacks categorized Medical/Dental-Supplies industry. The company has been actively pursuing acquisitions to strengthen its core areas and diversify businesses. The MWI Veterinary acquisition has diversified the company’s existing pharmaceutical distribution & services businesses into the attractive animal health market, which holds huge potential at the moment. The acquisition of PharMEDium added to AmerisourceBergen’s ability to provide market-leading services and solutions to its health system customers. " (2/21/2017)
• 2. Leerink Swann analysts commented, "We note that even with the impact of the fire, comp trends improved across divisions; absent the fire, core Gap, while still at a disappointing -5% comp, would have seen an 8 and 9 point improvement on a 2 and 3 stack vs. August, respectively." (10/7/2016)

Some companies that are related to AmerisourceBergen Corp. include Boston Scientific (BSX), Express Scripts Holding Company (ESRX), McKesson (MCK), Intuitive Surgical (ISRG), Humana (HUM), Baxter International (BAX), Zoetis (ZTS), HCA Holdings (HCA), Vertex Pharmaceuticals Incorporated (VRTX), Actelion Ltd (ALIOF), Essilor International SA (ESLOY), Teva Pharmaceutical Industries Ltd (TEVA), Luxottica Group SpA (LUX), Grifols SA, Barcelona (GRFS), Fresenius Medical Care AG & Co. (FMS), Incyte (INCY), Astellas Pharma (ALPMY) and Illumina (ILMN).

AmerisourceBergen Corp.'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (3.47%), Fiduciary Management Inc. WI (0.00%), JPMorgan Chase & Co. (0.00%) and Bank of New York Mellon Corp (1.41%). Company insiders that own AmerisourceBergen Corp. stock include Dale Danilewitz, Dermot Mark Durcan, Gina Clark, Henry Wadsworth Mcgee III, James F Cleary Jr, John G Chou, Kathy H Gaddes, Lazarus Krikorian, Lon R Greenberg, Richard C Gozon and Steven H Collis. View Institutional Ownership Trends for AmerisourceBergen Corp..

AmerisourceBergen Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Parametric Portfolio Associates LLC, Acadian Asset Management LLC, Janus Capital Management LLC, FMR LLC, Credit Agricole S A, Burgundy Asset Management Ltd. and State of Wisconsin Investment Board. Company insiders that have sold AmerisourceBergen Corp. stock in the last year include Gina Clark, Henry Wadsworth Mcgee III, John G Chou, Kathy H Gaddes, Lazarus Krikorian and Steven H Collis. View Insider Buying and Selling for AmerisourceBergen Corp..

AmerisourceBergen Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., FIL Ltd, Beutel Goodman & Co Ltd., Bank of America Corp DE, Morgan Stanley, Wells Fargo & Company MN, Fiduciary Management Inc. WI and Vanguard Group Inc.. Company insiders that have bought AmerisourceBergen Corp. stock in the last two years include Dermot Mark Durcan, James F Cleary Jr and Lon R Greenberg. View Insider Buying and Selling for AmerisourceBergen Corp..

Shares of AmerisourceBergen Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AmerisourceBergen Corp. stock can currently be purchased for approximately $91.00.